Day: August 10, 2022

DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the second quarter ended June 30, 2022. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We continue to advance our evolution towards becoming a fully-integrated biopharmaceutical company via our subsidiary ecosystem. Specifically, we are on track to open the Scorpion San Antonio biologics manufacturing facility in Q3 and are actively progressing development efforts for our newly-announced commercial scale biomanufacturing facility in Manhattan, Kansas. We intend to provide a full suite of CDMO manufacturing and bioanalytic services to biopharmaceutical...

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced financial results for the second quarter and six months ended June 30, 2022. Second Quarter and Recent HighlightsTotal revenue of $9.6 million in the second quarter of 2022, an increase of 35% over the second quarter of 2021 driven by strong growth in the cell therapy market; core business revenues grew 45% led by revenue from cell therapy customers which increased...

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2022. Second Quarter 2022 and Recent Corporate HighlightsU.S. Food and Drug Administration (FDA) acknowledged that data from a proposed randomized withdrawal phase of Study C602 would have the potential to address its concerns regarding the adequacy of the overall efficacy data supportive of a New Drug Application (NDA) submission for DCCR. Study C602 is an ongoing open-label extension study comprised of patients who completed DESTINY PWS, an international, multi-center, randomized, double-blind, placebo-controlled...

2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its second quarter 2022 financial results and provided a business update. “The second quarter of 2022 was another banner period of execution for ADMA Biologics,...

OREM, Utah, Aug. 10, 2022 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, today announced financial results for the second quarter of 2022. “The supply chain issues plaguing U.S industries have recently affected some of the Reflect products. Although we anticipated much of the shipping delays and parts availability, we were finally hit with some shortages. We have been diligently researching workarounds and replacements. I do not expect this situation to extend past the third quarter.” stated Mr. Kim Boyce, CEO of Reflect Scientific. The following unaudited table summarizes revenue, cost of goods sold, and operating expenses for the three months ended June 30, 2022 and 2021:         Three Months Ended...

OMAHA, Neb., Aug. 10, 2022 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (tZERO: EXOD, Securitize Markets: EXOD) (OTC: EXOD) (“the Company” or “Exodus”), the leading self-custodial cryptocurrency software platform, today announced its fiscal 2022 results for the second quarter ended June 30, 2022. The Company reported second quarter revenue of $13.0 million, a decrease of 53% year-over-year from Q2 2021, in-line with market trends. Second Quarter 2022 Financial HighlightsIn USD millions, except percentages Q2 2022 Q2 2021   % Change H1 2022 H1 2021 % ChangeRevenue $ 13.0   $ 27.7     (53 %) $ 28.4   $ 51.3   (45 %)Total Cost of Revenues   7.1     6.0     18 %   14.3     9.5   51 %Operating Expenses   10.8     7.2     50 %   19.7     11.6   70 %Income / (Loss) from Operations1   (4.9 )   14.5     (134 %)   (5.6 )   30.2   (119 %)Operating...